


Antech™

Nu.Q®

Rapid, Targeted Cancer Screening — From Sample to Results in Under 15 Minutes.



Nu.Q® on Element i+ is the industry's only in-house canine cancer screening blood test, exclusively offered by Antech

Nu.Q® utilizes breakthrough technology to help assess the current likelihood of certain cancers, including lymphoma and hemangiosarcoma.

Reliable and convenient in-house cancer screening test

Only requires 50µL of EDTA plasma from a patient.
High (>70%) detection rates for lymphoma.

Innovative cancer assessment

Measures canine plasma nucleosome concentration to help determine likelihood of certain cancers, oftentimes sooner than traditional wellness screening.

Affordable testing and immediate results

Refine your differential list in minutes, helping you inform pet owners of risk level for common cancer types — all at an affordable cost for pet owners.

Seamless integration into routine wellness

Efficient workflow makes it easy to add Nu.Q® to routine wellness diagnostics for high-risk patients.

Nu.Q® is a registered trademark of VolitionRx Limited and is supplied under license by Volition RX Limited and its subsidiaries 43868-001

Nu.Q® on Element i+ Offers Early Detection for Best Prognosis.

One in four dogs develop cancer,
and often diagnosed far too late.¹

Nu.Q® is an Accessible, Affordable,
and Quantitative Blood Test For
Plasma Nucleosomes in Dogs.

Indications:

- Older dogs (≥ 7 years of age)
- Younger dogs (≥ 4 years of age) for breeds known to be at a higher risk of developing cancer
 - Labrador Retriever
 - French Bulldog
 - Golden Retriever
 - German Shepherd
 - Beagle
 - Rottweiler
 - Boxer
 - Pembroke Welsh Corgi
 - Great Dane
 - Miniature schnauzer
 - Siberian Husky
 - Bernese Mountain Dog
 - Mastiff
 - Irish Wolfhound
 - Flat-coated Retriever
 - Scottish Wolfhound

Nucleosomes can become elevated before traditional wellness screening parameters alerting disease may be present sooner. Nu.Q® on the Element i+ also allows clinicians to interpret results and develop a plan of action before your patient goes home.

Determine the current likelihood of certain cancers like lymphoma and hemangiosarcoma with Nu.Q® instantly, with technology at your fingertips

PEER-REVIEWED STUDIES

Lymphoma paper: pubmed.ncbi.nlm.nih.gov/34399763

Hemangiosarcoma paper: pubmed.ncbi.nlm.nih.gov/34187493

2020 cancer vs healthy dogs: pubmed.ncbi.nlm.nih.gov/32866177

*Nu.Q® is not a confirmatory test for cancer. Nu.Q® results should act as an impetus to perform additional diagnostics to discern a diagnosis. Elevated plasma nucleosome concentration does not indicate which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q® cannot differentiate between cancer and an inflammatory response.

REFERENCES:

1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from avma.org/resources/pet-owners/petcare/cancer-pets
2. National Cancer Institute: ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-onc#:~:text=It%20has%20been%20estimated%20that,in%20cats%20made%20each%20year

Element i+™

Immunodiagnostic Analyzer

Supports diagnostic needs with total T4, cortisol, progesterone, cTSH, and the Nu.Q® cancer test.



In-clinic Nu.Q®

Discover the speed, accuracy, and flexibility of Element i+ combined with affordable, immediate in-house cancer risk evaluation using the Nu.Q® test

Learn more about how these systems can work for your clinic
0800 474 225 | poct.vets@awanuigroup.co.nz | awanuivets.co.nz/poct

